A Dose-Response Safety Study of ENX-102 in Patients With GAD

Clinical trial NCT06653296 · COMPLETED

Trial details

NCT number: NCT06653296
Sponsor: Engrail Therapeutics INC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

General Anxiety Disorder

Start date: 2024-12-09
Primary completion: 2025-06-23
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.